CN100346790C - Application of (+) North America coptisine - Google Patents
Application of (+) North America coptisine Download PDFInfo
- Publication number
- CN100346790C CN100346790C CNB021591709A CN02159170A CN100346790C CN 100346790 C CN100346790 C CN 100346790C CN B021591709 A CNB021591709 A CN B021591709A CN 02159170 A CN02159170 A CN 02159170A CN 100346790 C CN100346790 C CN 100346790C
- Authority
- CN
- China
- Prior art keywords
- hydrastine
- group
- learning
- memory
- hdst
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Abstract
The present invention relates to the application of (+)hydrastine to the preparation of medicine for preventing and treating aphrenia, promoting intelligence and improving oxygen deficiency resistance capability. Animal experiments prove that (+)hydrastine can improve the learning and memory capability of model small mice with aphrenia caused by scopolamine and pentobarbital sodium, can improve the learning and memory capability of normal small mice and old small mice, and can improve the survival time of small mice with oxygen deficiency. (+) hydrastine has the advantages of high activity and small toxicity.
Description
Technical field
The present invention relates to the application of (+) hydrastine in the medicine for preparing prevention and treatment dementia, the intelligence that promotes, raising hypoxia-bearing capability.Confirm that through zoopery (+) hydrastine can improve scopolamine, pentobarbital sodium causes the Model of Dementia learning and memory abilities in aging mice, improve the ability of learning and memory of normal mouse, aged mouse, improve the life span of anoxia mice.(+) hydrastine has the advantage that activity is high, therapeutic dose toxicity is little.
Background technology
The average life of China's population is above 70 years old at present.External scientific research prediction: the old people of 65 years old and over-65s will reach 18.8% during by 2025, and this numeral shows, surplus 20 year, per 5 philtrums just have 1 old people.Degenerative brain disorder (Alzheimer ' sDisease) mostly occurs year surplus 50.The multiple embolism dementia or the alzheimer disease that cause because of cerebrovascular disease mostly occurred after 60 years old.As seen, because the aging of population, the sickness rate of degenerative brain disorder and senile dementia also will increase.Old people and distinctive neurodegenerative disease thereof---various dementias will experience two kinds of death, at first are spiritual death, after be sensual death, suffer untold misery, bring heavy burden more for society and family.Aged tendency of population is considered to be only second to war, pestilence, famine, energy resource shortage and influence social development and stabile unfavorable factor.
Dull-witted (dementia) is the acquired and persistence disturbance of intelligence syndrome that produces owing to disordered brain function, disturbance of intelligence comprises that in various degree memory, language, visual space function, abnormality of personality and cognitive competence reduce, and dementia mainly comprises Alzheimer disease, vascular dementia etc.Control medicament categories old and feeble and the treatment senile dementia is various.Mainly use cholinergic drug clinically at present or cholinesterase inhibitor is treated, be aided with to improve cerebrovascular circulation, cerebral protective agent etc., effect is often not satisfactory.Strengthen in the medicine of choline systemic-function, the Ach precursor only has faint therapeutical effect, though Ach receptor stimulating agent and cholinesterase inhibitor have certain effect, acts on ofer short durationly, and toxic and side effects is bigger.Cerebral vasodilator help to provide energy and improve intelligence by improving cerebral blood flow, but real valuable cerebral vasodilator must have high selectivity, does not influence the brain metabolism, does not have " stealing blood " phenomenon, and antiplatelet aggregation and anti thrombotic action are arranged.Though the calcium antagonist nimodipine meets above-mentioned some condition, it only acts on the L-passage in the voltage dependent channel, and N type and T type calcium channel are not had influence.Multiple neuropeptide and nerve growth factor once were considered to the hope of treatment dementia, but clinical effectiveness is not good, may be mainly were difficult to enter in the brain by blood brain barrier owing to this class material play a role.After 2-Pyrrolidone acetamide (trade name piracetam) comes out, belong to the not novel nootropics of a class of arguement in early days in the document, reported both at home and abroad in recent years, this medicine slightly or does not still have final conclusion to all types of dysmnesia and senile dementia effect, it is a water soluble compound, the blood brain barrier percent of pass is low, is difficult for focusing on target spot and plays a role.
(+) hydrastine is from a kind of alkaloid monomer that extracts the geographic plant of NORTHWEST CHINA-straight stem Herba corydalis edulis (Corydalis stricta Steph.) that is grown in, be soluble in acid flux material, adjust pH value with alkaline solution and be no more than at 4 o'clock, biological activity is stable, and precipitation does not appear in long preservation.Known (the square departure of (+) hydrastine, Lin Mao, Weng Qingmei, Zhu Chaode, Liu Xin. the chemical research of four kinds of Corydalis plant alkaloids of the chemistry of Corydalis plant alkaloid---Part of Qinghai Plateau. Acta Pharmaceutica Sinica, 1981,16 (10): 798-800.), but the research of its biological activity aspect does not appear in the newspapers so far.
Summary of the invention
In order to overcome the deficiencies in the prior art, the object of the present invention is to provide the application of a kind of (+) hydrastine shown in general formula (I) in the medicine for preparing prevention and treatment dementia, the intelligence that promotes, raising hypoxia-bearing capability.
Another object of the present invention provides pharmaceutical composition, comprising as carrier commonly used in (+) hydrastine shown in general formula (I) of effective ingredient and the pharmaceutical field.
Chemical compound of the present invention comprises acceptable salt on its derivant, stereoisomer and the pharmacodynamics.
Specifically, one aspect of the present invention relates to the chemical compound shown in general formula (I)
(+) hydrastine can improve the learning memory disorder that multiple reason causes.Intraperitoneal administration 0.15mg/kg (be about median lethal dose(LD 50) 1/20) and oral administration 0.625mg/kg (be about median lethal dose(LD 50) 1/40), obviously prolong the incubation period that can make animal enter electric shock district, darkroom, and the errors number of appearance obviously reduces.The pharmacological results is presented in advance the abdominal cavity and awards behind (+) hydrastine 0.15mg/kg lumbar injection scopolamine 1.0mg/kg again, and the number of times of mistake is 0%.Return to the level of normal group incubation period fully, illustrates to have reversed the detrimental effect that scopolamine obtains mouse memory fully.Illustrate that (+) hydrastine can effectively improve the learning and memory obstacle that the anticholinergic agent scopolamine causes.
Equally, the learning memory disorder that pentobarbital sodium (Pentobarbital) is caused also has tangible inverting action.In darkroom test, mouse peritoneal injection (+) hydrastine 0.15mg/kg increases incubation period, and the number of times of mistake reduces, and is remarkable with the model group comparing difference.Illustrate that (+) hydrastine can effectively improve the learning and memory obstacle that pentobarbital sodium causes, and significantly be better than the cholinesterase inhibitor tacrine (Tacrine) and the calcium antagonist nimodipine (Nimodipine) of external listing.
In water maze test, the mice of oral 0.625mg/kg (+) hydrastine group is swum to the shortening of platform time ratio model group, and also lacks than the normal control group, and errors number is still lacked than the normal control group.With model group ratio, difference highly significant.Illustrate that (+) hydrastine can effectively improve the learning and memory obstacle that pentobarbital sodium causes, and be better than nimodipine.
For the intact animal, on the animal model of water maze, also shown the effect of good enhancing learning and memory.The animal of having given (+) hydrastine obviously strengthens than the normal control group ability of learning and memory of administration not, and it is short not only to arrive at the security platform required time, and it is also few to go to the wrong way the number of times of route in water maze.Through repeatedly repeating all to show this result.Result of the test shows no matter be that errors number is few than normal group, swimming time is short than normal group, demonstrates tangible nootropic effect.Effect is better than nimodipine and piracetam.
(+) hydrastine that further studies show that of the present invention can improve and strengthen aged learning and memory in rats and mice significantly.Aged male mice is poorer than young learning and memory abilities in aging mice really, and it is many and long that its errors number and trip reach all more young normal mouse of required time of security platform.But behind oral 0.625mg/kg (+) hydrastine, no matter be buck, or jenny, no matter be the time of arriving at security platform, the number of times that still makes a mistake has all shown the effect that improves and strengthen learning and memory.Not only compare significant difference, arrive at the time of security platform and the number of times that makes a mistake even all lack and lack than normal young control with the normal aged animal of not administration.
Except the ability of the learning and memory of above-mentioned raising animal, the present invention finds that also (+) hydrastine has tangible oxygen lack resistant function.No matter be an oral administration, or successive administration 30 days, all can prolong the life span of Hypoxia and ischemia animal head, and demonstrate dose-effect relationship preferably.
In addition, (+) hydrastine toxicity is low, and therapeutic dose is safe.
Therefore the present invention also relates to and containing as the chemical compound of the present invention of active ingredient and the pharmaceutical composition of conventional medicine excipient or adjuvant.Usually pharmaceutical composition of the present invention contains the The compounds of this invention of 0.1-95 weight %.
The pharmaceutical composition of The compounds of this invention can be according to method preparation well known in the art.When being used for this purpose, if desired, chemical compound of the present invention and one or more solids or liquid medicine excipient and/or adjuvant can be combined, make and can be used as suitable administration form or the dosage form that people's medicine or veterinary drug use.
The compounds of this invention or contain its pharmaceutical composition can the unit dosage form administration, route of administration can be intestinal or non-intestinal, as oral, muscle, subcutaneous, nasal cavity, oral mucosa, skin, peritoneum or rectum etc., preferred oral.
The compounds of this invention or the route of administration that contains its pharmaceutical composition can be drug administration by injection.Injection comprises intravenous injection, intramuscular injection, subcutaneous injection and intradermal injection etc.
Form of administration can be liquid dosage form, solid dosage forms.As liquid dosage form can be true solution class, colloidal type, particulate formulations, emulsion dosage form, mixed suspension form.Other dosage forms are tablet, capsule, drop pill, aerosol, pill, powder, solution, suspensoid, Emulsion, granule, suppository, lyophilized injectable powder etc. for example.
The compounds of this invention can be made ordinary preparation, also can be slow releasing preparation, controlled release preparation, targeting preparation and various particulate delivery system.
For the unit form of administration is made tablet, can be extensive use of various carrier well known in the art.Example about carrier is, for example diluent and absorbent are as starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, carbamide, calcium carbonate, kaolin, microcrystalline Cellulose, aluminium silicate etc.; Wetting agent and binding agent are as water, glycerol, Polyethylene Glycol, ethanol, propanol, starch slurry, dextrin, syrup, Mel, glucose solution, mucialga of arabic gummy, gelatine size, sodium carboxymethyl cellulose, lac, methylcellulose, potassium phosphate, polyvinylpyrrolidone etc.; Disintegrating agent, for example dry starch, alginate, agar powder, laminaran, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene sorbitol fatty acid ester, dodecyl sodium sulfate, methylcellulose, ethyl cellulose etc.; Disintegrate inhibitor, for example sucrose, glyceryl tristearate, cocoa butter, hydrogenation wet goods; Absorption enhancer, for example quaternary ammonium salt, sodium lauryl sulphate etc.; Lubricant, for example Pulvis Talci, silicon dioxide, corn starch, stearate, boric acid, liquid paraffin, Polyethylene Glycol etc.Tablet further can also be made coated tablet, for example sugar coated tablet, thin membrane coated tablet, ECT, or double-layer tablet and multilayer tablet.
For example, can be extensive use of various carrier well known in the art for pill is made in the administration unit.Example about carrier is, for example diluent and absorbent are as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinylpyrrolidone, Gelucire, Kaolin, Pulvis Talci etc.; Binding agent is as arabic gum, Tragacanth, gelatin, ethanol, Mel, liquid sugar, rice paste or batter etc.; Disintegrating agent is as agar powder, dry starch, alginate, dodecyl sodium sulfate, methylcellulose, ethyl cellulose etc.
For example for capsule is made in the administration unit, the effective ingredient The compounds of this invention is mixed with above-mentioned various carriers, and the mixture that will obtain thus places hard gelatine capsule or soft capsule.Also the effective ingredient The compounds of this invention can be made microcapsule, be suspended in and form suspensoid in the aqueous medium, in the hard capsule of also can packing into or make injection and use.
For example, The compounds of this invention is made injection preparation, as solution, suspensoid solution, Emulsion, lyophilized injectable powder, this preparation can be moisture or non-water, can contain acceptable carrier, diluent, binding agent, lubricant, antiseptic, surfactant or dispersant on a kind of and/or multiple pharmacodynamics.Can be selected from water, ethanol, Polyethylene Glycol, 1 as diluent, the isooctadecanol of ammediol, ethoxylation, the isooctadecanol of polyoxyization, Polyoxyethylene Sorbitol Fatty Acid Esters etc.In addition, ooze injection, can in injection preparation, add proper amount of sodium chloride, glucose or glycerol, in addition, can also add conventional cosolvent, buffer agent, pH regulator agent etc. in order to prepare etc.These adjuvants are that this area is commonly used.
In addition, as needs, also can in pharmaceutical preparation, add coloring agent, antiseptic, spice, correctives, sweeting agent or other material.
For reaching the medication purpose, strengthen therapeutic effect, medicine of the present invention or pharmaceutical composition can be with any known medication administrations.
The dosage of The compounds of this invention, pharmaceutical composition depends on many factors, for example to prevent or treat the character and the order of severity of disease, the sex of patient or animal, age, body weight, personality and individual reaction, route of administration, administration number of times, therapeutic purposes, therefore therapeutic dose of the present invention can have large-scale variation.In general, the using dosage of Chinese materia medica composition of the present invention is well known to a person skilled in the art.Can be according to the actual drug quantity that is contained in the preparation last in the The compounds of this invention compositions, in addition suitable adjustment to reach the requirement of its treatment effective dose, is finished prevention of the present invention or therapeutic purposes.The consumption of the suitable dose scope chemical compound of the present invention of the every day of The compounds of this invention is the 0.001-150mg/kg body weight, is preferably the 0.01-100mg/kg body weight, and more preferably the 0.01-60mg/kg body weight most preferably is the 0.1-10mg/kg body weight.Above-mentioned dosage can the single dose form or be divided into several, for example two, three or four dosage form administrations this be subject to administration doctor's clinical experience and comprise the dosage regimen of using other treatment means.
Each treats that required accumulated dose can be divided into repeatedly or by the dose administration.Chemical compound of the present invention, compositions can be taken separately, or merge use and adjust dosage with other treatment medicine or symptomatic drugs.
The specific embodiment
The following examples are used for further specifying the present invention, but this and do not mean that any limitation of the invention.
Darkness avoidance test: belong to disposable training passive avoidance experiment, this method utilizes mice to have a liking for dark habit design.Experimental provision is divided into light and shade two Room, has a hole to connect, and bright chamber is the place of safety, does not have; The darkroom is the electric shock district, and the bottom is the copper grid, passes to 40 volts of alternating currents.Animal creeps into the darkroom and is promptly shocked by electricity, and flees back bright chamber and can hide noxious stimulation.Experiment is divided into to be carried out in two days, and first day is training, test after 24 hours.Acquisition that this promptly remembers and maintenance test, the number of times that the record mice is shocked by electricity is as the percentage rate (i.e. the number of elements of the mice that appearance is wrong accounts for the percentage rate of this group mice number of elements) of errors number and mistake in computation.Mice from counting begin to the time that enters for the first time the darkroom be incubation period.Mistake is few, long show memory well incubation period, and mistake is many, lack show poor memory incubation period.
Maze learning is a kind of identification learning of locus.Depth of water 10cm in the water maze, water temperature is controlled at about 25 ℃, has a cat ladder, animal to climb out of the water surface in the target area and obtains to have a rest.Experiment divides three phases to carry out.Phase I at the A place, makes animal begin training from A on the baffle plate retaining, and only as training usefulness, the 1-2 time, time and errors number do not take statistics at the A place.Prolong the swimming path of animal starting area to target area gradually, increase the cecum district simultaneously.Second stage at the B place, makes animal begin training, the 3-6 time from B on the baffle plate retaining.Phase III, at the C place, make animal begin training, the 7-9 time on the baffle plate retaining from C.See sketch map, 1,2,3,4 is cecum among the figure, and animal is swum into cecum and represents mistake.The time that arrives the ladder security platform from each training is the needed time of swimming.The number of times that enters cecum is few, and short expression of the time of swimming required learning and memory is good.Otherwise then poor, or be referred to as learning memory disorder.This method can detect the ability of animal spatial orientation and learning and memory.
Alzheimer disease is lost the most serious with the basal forebrain cholinergic neuron, cause the acetylcholine hyposecretion.Scopolamine is the M cholinergic receptor-blocking agent, can suppress the agonism of acetylcholine to m receptor, therefore can imitate the insufficient result of cholinergic function, is one of animal model of research alzheimer disease.
HDST: the abbreviation that is (+) hydrastine.
SCOP: the abbreviation of expression scopolamine.
NMDP: the abbreviation of nimodipine.
Tac: the abbreviation of tacrine.
PTB: the abbreviation of pentobarbital sodium.
The unit of all dosage is mg/kg.
Embodiment 1 (+) hydrastine causes the effect (darkness avoidance test) of memory acquisition disturbance to scopolamine
50 of kunming mices are divided into 5 groups at random: the normal control group, scopolamine destroys memory models group, (+) hydrastine 0.075mg/kg, 0.15mg/kg, three dosage groups of 0.30mg/kg.Compare with the normal control group, behind the lumbar injection scopolamine 1.0mg/kg, make wrong percentage rate reach 60%, shortened 90 seconds incubation period, remarkable with the matched group comparing difference, the learning and memory that the prompting scopolamine can significantly destroy animal obtains.After the abdominal cavity awards (+) hydrastine in advance, train, the test of reforming after 24 hours the results are shown in Table 1
Table 1
| Group | Dosage | Errors number | Incubation period (second) | Mistake % |
| Normal control group SCOP HDST+SCOP HDST+SCOP HDST+SCOP | 1.0 0.075+1.0 0.15+1.0 0.30+1.0 | 0.0±0.0 0.6±0.5 ++ 0.4±0.5 0.0±0.0 0.4±0.7 | 299.0±0.0 210.0±84.4 ++ 231.2±93.0 299±0.0 ** 262.7±62.4 | 0 60 ++ 40 0 ** 30 |
N=10, X ± SD, ++ P＜0.01 vs matched group, * * P＜0.01 vs SCOP
Experimental result is presented in advance the abdominal cavity and awards behind (+) hydrastine 0.15mg/kg lumbar injection scopolamine 1.0mg/kg again, and the number of times of mistake is 0%.Incubation period is identical with the normal control group, returns to the level of normal group fully, illustrates to have reversed the detrimental effect that scopolamine obtains mouse memory fully.Illustrate that (+) hydrastine can effectively improve the learning and memory obstacle that the anticholinergic agent scopolamine causes.
Embodiment 2 (+) hydrastine causes the effect (darkness avoidance test) of memory acquisition disturbance to pentobarbital sodium
60 of kunming mices are divided into 6 groups at random: the normal control group, pentobarbital sodium destroys memory models group, tacrine group, (+) hydrastine 0.075mg/kg, 0.15mg/kg, three dosage groups of 0.30mg/kg.Subcutaneous injection pentobarbital sodium 25mg/kg can destroy learning and memory in rats and mice significantly, and shortened to 65.9 second from 275.8 seconds incubation period, and the percentage rate of mistake is increased to 90% from 10%.The results are shown in Table 2
Table 2
| Group | Dosage | Errors number | Incubation period (second) | Mistake % |
| Matched group PTB Tac+PTB HDST+PTB HDST+PTB HDST+PTB | 25 1.5+25 0.075+25 0.15+25 0.30+25 | 0.1±0.3 1.4±1.0 ++ 1.3±0.7 1.1±0.8 0.4±0.5* 0.6±0.5* | 275.8±69.6 65.9±84.8 ++ 57.5±52.9 89.2±113.5 220.8±103.8** 178.0±108.0* | 10 90 ++ 100 70 40* 60 |
N=10, X ± SD, ++ P＜0.01 vs matched group, * P＜0.05 vs PTB, * * P＜0.01vsPTB.
Lumbar injection (+) hydrastine 0.15mg/kg incubation period is 220.8 seconds, and the number of times of mistake is 40%, with model group P＜0.01 and＜0.05 relatively, significant difference.Tacrine 1.5mg/kg does not show any effect, and be 57.5 seconds incubation period, and the percentage rate of mistake is 100%.Illustrate that (+) hydrastine can effectively improve the learning and memory obstacle that pentobarbital sodium causes, and be better than tacrine.
The influence (water maze test) of the learning memory disorder that embodiment 3 (+) hydrastine causes pentobarbital sodium
60 of kunming mices, be divided into 6 groups at random: the normal control group, pentobarbital sodium lumbar injection 15mg/kg destroys the memory models group, nimodipine (Nimodipine, NMDP) group, the oral 2.5mg/kg of (+) hydrastine, 1.25mg/kg, three dosage groups of 0.625mg/kg (be respectively median lethal dose(LD 50) 1/10,1/20,1/40).Experimental result shows that pentobarbital sodium 15mg/kg is broken to have encircled ability of learning and memory in mice, swims to compare with 12.2 seconds of matched group to have prolonged 1/3 to time of security platform, and be 18.0 seconds, significant difference (P＜0.05).The number of times of mistake is 2.4, and comparing to some extent than matched group (1.7 times) increases, but statistical discrepancy is not remarkable.The results are shown in Table 3
Table 3
| Group | Dosage (mg/kg) | Errors number | Time (second) |
| Matched group PTB NMDP+PTB HDST+PTB HDST+PTB HDST+PTB | 15 1.0+15 0.625+15 1.25+15 2.50+15 | 1.7±0.6 2.4±1.0 2.1±1.3 1.0±0.5** 2.0±1.4 1.8±1.4 | 12.2±4.3 18.0±8.0+ 15.2±6.7 8.7±2.4** 13.4±7.2 13.6±9.2 |
N=10, X ± SD ,+P＜0.05 vs matched group, * * P＜0.01vs PTB.
Oral 0.625mg/kg (+) hydrastine group is swum to the platform time and has only been spent 8.7 seconds, has not only shortened nearly 10 seconds than model group, and lacks than the normal control group and to have spent 3.5 seconds.Errors number 1.0 is also lacked 0.7 time than the normal control group.With model group ratio, difference highly significant, the P value all＜0.01.And oral 1mg/kg nimodipine group is swum to the not shortening of platform time, though errors number has minimizing, statistical disposition is all not remarkable.Illustrate that (+) hydrastine can effectively improve the learning and memory obstacle that pentobarbital sodium causes, and be better than nimodipine.
Embodiment 4 (+) hydrastine is to the influence (water maze test) of normal learning and memory of little mouse
50 of kunming mices are divided into 5 groups at random, 10 every group: normal control group, oral nimodipine 1mg/kg group, oral (+) hydrastine 0.625mg/kg, 1.25mg/kg, three dosage groups of 2.5mg/kg.Just allow for the 1st and the 2nd time animal be familiar with the condition training, do not note down.The results are shown in following table 4
Table 4 (+) hydrastine is to the influence of normal learning and memory of little mouse
| Group | Dosage (mg/kg) | The errors number of B place test | |||
| 3 | 4 | 5 | 6 | ||
| Matched group NMDP HDST HDST HDST | 1 0.625 1.25 2.50 | 3.9±1.9 3.2±1.1 2.4±1.3 2.2±0.8** 2.5±0.8** | 2.6±1.4 1.5±0.7** 1.2±0.5** 1.6±0.6** 1.8±0.7* | 2.3±1.6 1.6±1.5 0.8±6.4** 1.2±0.8* 1.0±0.6** | 1.6±0.8 0.8±0.7* 0.3±0.4** 0.8±0.7* 0.8±0.5** |
N=10, X ± SD, * P＜0.05, * * P＜0.01 vs matched group.
| Group | Dosage (mg/kg) | The swimming time (second) of B place test | |||
| 3 | 4 | 5 | 6 | ||
| Matched group NMDP HDST HDST HDST | 1 0.625 1.25 2.50 | 24.3±12.1 20.0±7.4 15.9±5.7* 12.6±3.2** 20.0±11.4 | 16.5±13.1 13.0±5.7 9.5±1.6* 9.9±3.0* 13.6±7.4* | 13.1±8.7 11.4±9.2 8.4±3.1* 9.6±2.7 9.5±23.6 | 9.2±3.9 8.0±2.5 6.9±2.1 8.2±2.0 8.2±2.9 |
N=10, X ± SD, * P＜0.05, * * P＜0.01 vs matched group.
From the result of table 4 as can be seen (+) hydrastine show the improvement effect when the 3rd test.No matter be that errors number is few than normal group, swimming time is also short than normal group, demonstrates tangible nootropic effect.The nimodipine of 1mg/kg also has certain nootropic effect, but it is strong to be not so good as 0.625mg/kg (+) hydrastine.
Embodiment 5 (+) hydrastine and nimodipine, piracetam are to the comparison (water maze test) of the effect of normal learning and memory of little mouse
40 of kunming mices are divided into 4 groups at random, 10 every group: normal control group, oral nimodipine 1mg/kg group, oral piracetam 400mg/kg group, oral (+) hydrastine 0.625mg/kg group.Just allow for the 1st and the 2nd time animal be familiar with the condition training, do not note down.The results are shown in following table
Table 5 (+) hydrastine and nimodipine, piracetam
Comparison to the effect of normal learning and memory of little mouse
| Group | Dosage mg/kg | Errors number | |||||
| 3 | 4 | 5 | 6 | 7 | 8 | ||
| Matched group HDST NMDP piracetam | 0.625 1 400 | 5.56±2.31 3.24±1.09** 4.45±3.15 3.71±2.49 | 4.2±2.63 2.05±1.16* 2.7±2.85 2.12±2.28 | 1.9±1.63 1.79±0.89 2.5±2.76 1.87±1.08 | 1.65±1.18 0.6±0.39* 1.1±0.59 1.06±0.26 | 1.58±0.1 0.8±0.5* 1.06±0.7 1.23±0.6 | 1.06±0.5 0.61±0.46 1.17±0.77 1.37±0.73 |
N=10, X ± SD, * P＜0.05, * * P＜0.01 vs matched group.
| Group | Dosage mg/kg | Swimming time (second) | |||||
| 3 | 4 | 5 | 6 | 7 | 8 | ||
| Matched group HDST NMDP piracetam | 0.625 1 400 | 37.6±14.86 23.01±6.19** 28.9±17.67 25.24±12.31 | 38.4±24.9 14.9±4.04* 18.49±14.85* 17.76±13.52* | 16.7±10.9 17.1±8.5 15.9±12.2 15.6±5.6 | 15.27±9.53 8±1.56* 11.3±4.5* 10.3±2.38 | 17.33±8.6 8.73±2.01** 10.37±3.95* 11.54±2.46 | 10.5±3.47 8.8±2.37 12.19±4.41 13.7±4.35 |
N=10, X ± SD, * P＜0.05, * * P＜0.01 vs matched group.
Oral as can be seen 0.625mg/kg (+) hydrastine still shows fabulous nootropic effect from the result of table 5.The time of its wrong number of times and arrival security platform almost has only half of normal young matched group.Nimodipine also has certain effect, but it is obvious to can not show a candle to (+) hydrastine.The piracetam of oral 400mg/kg has the trend that strengthens ability of learning and memory, but statistical disposition difference does not have significance.Illustrate that (+) hydrastine is better than nimodipine, piracetam to the effect of normal learning and memory of little mouse.
Embodiment 6 (+) hydrastine is to the influence (water maze test) of male aged mouse learning and memory
Male aged mouse is planted a Mus for breeding old and feeble eliminating, and is continued to feed 4-6 month by the inventor.40 of male aged kunming mices, 10 of normal young mices are tested with water maze.Experimental result sees Table 6
Table 6 (+) hydrastine is to the influence of male aged mouse learning and memory
| Group | Dosage mg/kg | The errors number of test | |||||
| 3 | 4 | 5 | 6 | 7 | 8 | ||
| Aged matched group HDST HDST HDST young control: | 0.625 1.25 2.50 | 4.40±2.06 2.51±1.09* 2.10±0.73** 2.23±1.43 2.65±0.99 | 2.50±1.56 1.07±0.59* 1.50±0.84 1.23±1.29 1.85±0.66 | 3.33±2.67 1.26±0.87* 1.78±1.14 1.30±1.08 2.80±1.40 | 2.60±2.43 0.56±0.33 1.66±1.09 0.80±1.13 1.30±1.02 | 1.73±1.40 0.92±0.82 1.30±0.48 0.92±0.82 1.51±1.05 | 0.89±1.15 0.56±0.44 0.88±0.60 0.80±0.24 0.89±0.74 |
N=10, X ± SD, * P＜0.05, * * P＜0.01 vs Old (aged matched group).
| Group | Dosage | The swimming time (second) of test | |||||
| 3 | 4 | 5 | 6 | 7 | 8 | ||
| Aged matched group HDST HDST HDST young control: | 0.625 1.25 2.50 | 30.93±14.29 21.40±7.84 22.29±8.49 17.22±9.49 18.93±6.13* | 23.70±13.45 14.26±4.35 15.43±6.36 14.23±7.24 18.00±7.98 | 31.23±20.58 14.36±5.31* 17.14±8.20 12.05±7.43 19.34±8.44 | 23.04±15.40 11.03±2.18* 18.78±9.33 10.74±6.57 13.31±4.99 | 18.66±14.72 12.20±3.40 16.21±7.04 12.54±3.99 17.14±8.45 | 15.56±10.50 12.72±4.27 14.13±5.85 11.20±3.96 12.06±5.04 |
N=10, X ± SD, * P＜0.05, * * P＜0.01 vs Old (aged matched group).
From table the result as can be seen, aged male mice is poorer than young learning and memory abilities in aging mice really, it is many and long that its errors number and trip reach all more young normal mouse of required time of security platform.But aged Mus its wrong number of times after taking (+) hydrastine 0.625mg/kg almost has only aged Mus half.The 6th time, its errors number is 1/5 (0.56 ratio 2.60 times) of aged Mus, and shows shorter and lack than young normal control group once more.
Embodiment 7 (+) hydrastine is to the influence (water maze test) of female aged mouse learning and memory
Female aged mouse is planted a Mus for breeding old and feeble eliminating, and is continued to feed 4-6 month by the inventor.40 of female aged kunming mices, 10 of normal young mices are tested with water maze.Experimental result sees Table 7
Table 7 (+) hydrastine is to the influence of female aged mouse learning and memory
| Group | Dosage | The errors number of test | ||||||
| 3 | 4 | 5 | 6 | 7 | 8 | 9 | ||
| Aged matched group HDST HDST HDST young control: | 0.625 1.25 2.50 | 3.41±1.43 2.73±1.29 2.05±0.68 1.88±0.82 2.20±0.87 | 2.83±1.29 1.26±1.06** 1.74±1.00 2.16±1.00 1.97±0.81 | 1.97±0.96 1.12±0.71* 1.28±0.44 1.16±0.76 2.19±0.99 | 0.99±0.87 0.90±0.49 1.24±0.67 1.63±1.07 1.23±0.73 | 1.43±0.73 0.81±0.67 1.56±1.01 1.38±1.05 1.38±1.07 | 1.21±0.81 1.11±0.84 1.23±0.73 1.18±0.70 1.52±0.68 | 0.75±0.68 0.65±0.87 1.05±0.96 0.69±0.66 0.85±0.45 |
N=10, X ± SD, * P＜0.05, the aged matched group of * * P＜0.01 vs.
| Group | Dosage | The swimming time (second) of test | ||||||
| 3 | 4 | 5 | 6 | 7 | 8 | 9 | ||
| Aged matched group HDST HDST HDST young control: | 0.625 1.25 2.50 | 29.36±10.95 21.13±10.45 16.58±3.50** 18.89±7.00* 16.71±6.31** | 24.95±12.38 13.70±7.51* 19.34±6.50 23.13±6.84 17.53±5.37 | 19.53±10.14 11.63±3.63* 14.09±5.30 17.34±8.56 16.27±6.03 | 14.07±7.51 10.60±3.62 14.26±4.39 18.39±8.18 12.16±5.99 | 16.20±6.62 10.63±3.05* 14.37±5.55 14.96±4.83 13.56±5.91 | 12.98±3.95 11.07±4.60 12.11±2.79 13.45±3.08 13.94±3.68 | 11.65±2.92 10.65±5.39 12.25±4.53 12.00±4.49 10.95±3.34 |
N=10, X ± SD, * P＜0.05, the aged matched group of * * P＜0.01 vs.
Table 7 experimental result shows similar substantially to aged male Mus, just a little less than the effect slightly.The result of consolidated statement 6 and table 7 can affirm that (+) hydrastine has the amnemonic effect of the aged animal learning of improvement.
Embodiment 8 (+) hydrastine oral administration is to the influence of mice hypoxia-bearing capability
40 of kunming mices are divided into 4 groups at random, 10 every group: normal control group, oral (+) hydrastine 0.625mg/kg, 1.25mg/kg, three dosage groups of 2.5mg/kg.Use 380ml ground transparent agent bottle, mice is put into bottle, cover tight bottle stopper and seal observation mice time-to-live in bottle with vaseline.Each administration group is carried out the t check with the normal control group respectively.
Oral administration of table 8a (+) hydrastine is to the influence of mice oxygen-resistant ability.
| Group | Dosage | Body weight (gram) | Time-to-live (minute) |
| Matched group hydrastine hydrastine hydrastine | 0.625 1.25 2.50 | 23.0±0.9 23.0±0.8 22.3±1.2 22.5±0.8 | 45.0±6.4 47.8±10.6 50.5±5.3 * 54.0±6.7 ** |
N=10, X ± SD, * P＜0.05, * * P＜0.01 vs matched group.
Continuous 30 days oral administrations of table 8b (+) hydrastine are to the influence of mice oxygen-resistant ability.
| Group | Dosage | Time-to-live (minute) |
| Matched group hydrastine hydrastine hydrastine | 0.625 1.25 2.50 | 24.0±3.4 26.6±1.7 31.4±3.1 ** 31.0±3.9 ** |
N=10, X ± SD, * P＜0.05, * * P＜0.01 vs matched group.
Test explanation (+) hydrastine has tangible oxygen lack resistant function.No matter be an oral administration, or continuous oral administration 30 days, all can prolong the life span of Hypoxia and ischemia animal head, and demonstrate dose-effect relationship preferably.
The toxicity (LD50) of embodiment 9 (+) hydrastine
Iv intravenous injection 0.27 (0.25-0.29) mg/kg
Ip lumbar injection 2.85 ± 0.39mg/kg
Po oral administration 25.8 ± 1.0mg/kg
Claims (1)
1, the application of (+) hydrastine shown in general formula (I) in the medicine of preparation prevention or treatment dementia,
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021591709A CN100346790C (en) | 2002-12-30 | 2002-12-30 | Application of (+) North America coptisine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021591709A CN100346790C (en) | 2002-12-30 | 2002-12-30 | Application of (+) North America coptisine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1511525A CN1511525A (en) | 2004-07-14 |
| CN100346790C true CN100346790C (en) | 2007-11-07 |
Family
ID=34237347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021591709A Expired - Lifetime CN100346790C (en) | 2002-12-30 | 2002-12-30 | Application of (+) North America coptisine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100346790C (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002100329A2 (en) * | 2001-06-08 | 2002-12-19 | Peninsula International, Llc | Methods and compositions for helping the body resist the effects of the aging process |
-
2002
- 2002-12-30 CN CNB021591709A patent/CN100346790C/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002100329A2 (en) * | 2001-06-08 | 2002-12-19 | Peninsula International, Llc | Methods and compositions for helping the body resist the effects of the aging process |
Non-Patent Citations (3)
| Title |
|---|
| 北美黄连主要生物碱的提取与分离 董新荣，等.精细化工中间体，第31卷第3期 2001 * |
| 右旋北美黄连碱的中枢兴奋作用 王丽韫，等.西北药学杂志，第12卷 1997 * |
| 我国神经药理学研究的主要进展－2001年全国神经药理研讨班张均田教授报告部分内容 齐尚斌.四川生理科学杂志，第23卷第3期 2001 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1511525A (en) | 2004-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8598225B2 (en) | Use of L-butylphthalide in the manufacture of medicaments for treatment of cerebral infarct | |
| BG106279A (en) | Treatment of neurotic disorders | |
| JP2016508489A (en) | Protopanaxadiol derivative, production method thereof and application thereof | |
| CN101015648B (en) | Use of succinic acid derivative eater compound for treating dementia | |
| CN110327356B (en) | Combination comprising limonoids and alpha-glucosidase inhibitors | |
| CN100346790C (en) | Application of (+) North America coptisine | |
| CN1531434A (en) | Selective dopamine D4 receptor agonists for treating sexual dysfuction | |
| EP1216039B1 (en) | Novel combination for the treatment of sexual dysfunction | |
| CN1857622A (en) | Medicine composition and preparation containing effective components of gastrodia tuber and Chuanxiong rhizome | |
| CN102049047A (en) | Drug combination | |
| KR20010072598A (en) | Acetylcholine Enhancers | |
| CN101062039B (en) | Medical combination for treating nervous system diseases | |
| CN109908162B (en) | Pharmaceutical composition for treating depression, preparation and medical application thereof | |
| CN102631397A (en) | Traditional Chinese medicine composition for improving cerebral blood circulation and preparation method thereof | |
| CN104706639B (en) | A kind of medical composition and its use for treating Male erectile dysfunction | |
| CN1245999C (en) | Use of seguinii in preparing medicine or food | |
| CN103169716A (en) | Compound medicinal composition for treating pain | |
| US20240122958A1 (en) | Beta-adrenergic agonist and muscarinic antagonist compositions and methods of using | |
| CN1163253C (en) | Mulberry mistletoe extract for preventing or treating anaphylactic reaction, medicinal composition containing it and its preparing process | |
| CN108079305A (en) | The medical composition and its use of cannabidiol and tricyclic antidepressant | |
| CN101450062A (en) | Medicine composition for treating melancholia using multi-target receptor after-action mechanism | |
| CN1099282A (en) | Compound lotus plumule liquid and its preparation | |
| HUT57584A (en) | Process for producing pharmaceutical compositions suitable for treating drug addiction and comprising dopamin-autoreceptor agonists | |
| CN1402638A (en) | Method of treating substance addiction | |
| CN116920101A (en) | New pharmaceutical composition for treating major depressive disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING LIANXIN PHARMACEUTIC CO., LTD. Free format text: FORMER OWNER: HUANG JUNHUA Effective date: 20130408 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100088 HAIDIAN, BEIJING TO: 100000 DAXING, BEIJING |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130408 Address after: 100000 Daxing District Beijing biological engineering and pharmaceutical industry base, nine Fu Tian Street Patentee after: BEIJING LIANXIN PHARMACEUTICAL Co.,Ltd. Address before: 100088 No. 1008, building 1, building 21, North Road, Haidian District Normal University, Beijing Patentee before: Huang Junhua |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20071107 |